Grace Therapeutics Inc Share Price

NASDAQ: GRCE

Small Cap

$3.08

-0.07

(-2.22%)

as on September 16, 2025 at 1:27 am IST

$₹

Grace Therapeutics Inc Stock Performance

as on September 16, 2025 at 1:27 am IST

Day's Low
Day's High
$3.05
Day's Price Range
$3.14
$3.08
0.97%
Downside
1.95%
Upside
52 Week's Low
52 Week's High
$1.75
52-Week Price Range
$4.97
$3.08
43.18%
Downside
61.20%
Upside

Grace Therapeutics Inc share price movements today

Previous Close: $3.15
Open: $3.10
Volume: 376.3K
Day's Low - High: $3.05 - $3.14
52 Week Low - High: $1.75 - $4.97

Grace Therapeutics Inc Historical Returns

1 Month Return: -3.37 %
3 Month Return: + 10.92 %
1 Year Return: 0 %
3 Year Return: 0 %
5 Year Return: 0 %

Grace Therapeutics Inc Stock Fundamentals & Key Indicators

Check Grace Therapeutics Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$35.0M

EPS (TTM)

-1.588

Dividend Yield

0.00%

PE Ratio (TTM)

P/B Ratio

PEG Ratio

Return On Equity TTM

12380900.00%

Grace Therapeutics Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Grace Therapeutics Inc with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %
Grace Therapeutics Inc	NA	$35.0M	NA	NA	0.00%
Alnylam Pharmaceuticals, Inc.	BUY	$61.1B	256.98%	-505.15	-12.96%
Beone Medicines Ltd	NA	$38.7B	NA	NA	-3.89%
Vertex Pharmaceuticals Incorporated	BUY	$101.1B	47.85%	28.07	31.86%
Regeneron Pharmaceuticals, Inc.	BUY	$59.4B	-3.43%	14.11	31.37%

Grace Therapeutics Inc Quarterly Profit & Loss

All numbers in Millions USD

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025
Total Revenue	-	-	-	-	-	-	-	0	-
Gross Profit	-	0	0	0	0	0	0	0	0
Operating Income	-4	-2	-3	-3	-4	-4	-3	-3	-3
EBITDA	-2	-2	-3	-4	-4	-4	-3	-3	-3
Interest Expense	-	-	-	-	-	-	-	-	-
Depreciation	0	0	0	0	0	0	0	0	0
Income Before Tax	-4	-3	-2	-4	-3	-4	-4	0	-3
Income Tax Expense	0	0	0	0	0	0	0	-1	-
Net Income	-4	-3	-2	-3	-2	-3	-4	0	-3
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	7950.00%	0.00%

Grace Therapeutics Inc Annual Profit & Loss

All numbers in Millions USD

	Mar 2015	Mar 2016	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Total Revenue	0	0	0	-	-	-	-
Gross Profit	0	0	0	-	0	0	0
Operating Income	-9	-7	-16	-15	-52	-12	-16
EBITDA	-8	-2	-9	-15	-18	-11	-12
Interest Expense	0	0	0	-	-	-	-
Depreciation	-	-	0	-	0	0	0
Income Before Tax	-1	-4	-19	-10	-51	-14	-12
Income Tax Expense	-	-	-	0	-9	-1	-3
Net Income	-1	-4	-19	-9	-42	-12	-12
Net Profit Margin	-611.68%	-16777.63%	-10039.80%	0.00%	0.00%	0.00%	0.00%

Grace Therapeutics Inc Quarterly Cash Flow

All numbers in Millions USD

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025
Net Income	-4	-3	-2	-3	-2	-3	-4	0	-3
Operating Cash Flow	-6	-2	-1	-2	-3	-4	-4	-2	-1
Investing Cash Flow	-	0	-6	6	0	0	0	-	-
Financing Cash Flow	-	7	0	0	-	-	-	14	0
Change in Cash	-6	5	-8	4	-3	-4	-4	11	-2

Grace Therapeutics Inc Annual Cash Flow

All numbers in Millions USD

	Mar 2016	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Net Income	-4	-16	-39	-25	-19	-9	-42	-12	-9
Operating Cash Flow	-4	-9	-24	-22	-14	-17	-15	-12	-14
Investing Cash Flow	6	0	-9	8	-9	-3	13	0	-
Financing Cash Flow	0	8	45	13	59	-	0	7	14
Change in Cash	1	-1	10	-2	36	-20	-2	-4	0

Insights on Grace Therapeutics Inc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

NO EFFECT
Against Peers
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 118.7% return, outperforming this stock by 149.7%
NO EFFECT
Against Peers
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 72.3% return, outperforming this stock by 50.0%
NEGATIVE IMPACT
Price Dip
In the last 7 days, GRCE stock has moved down by -3.4%

About Grace Therapeutics Inc

Grace Therapeutics, Inc. is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its novel drug delivery technologies have the potential to improve the performance of marketed drugs by achieving faster onset of action, and reduced side effects. Its lead clinical asset, GTx-104, is an intravenous infusion targeting aneurysmal Subarachnoid Hemorrhage (aSAH), a rare and life-threatening medical emergency in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull. The nanoparticle technology of GTx-104 facilitates aqueous formulation of insoluble nimodipine for a standard peripheral IV infusion. Its other pipeline includes GTX-102, which is targeted as the first potential therapy for the treatment of ataxia-telangiectasia (AT) in a pediatric population and GTx-101, which is a topical administration via a bioadhesive, film-forming polymer, for the treatment of pain associated with postherpetic neuralgia.

Organisation	Grace Therapeutics Inc
Headquarters	103 Carnegie Center, Princeton, NJ, United States, 08540
CEO	Mr. Prashant Kohli
E-voting on shares	Click here to vote

Key Management of Grace Therapeutics Inc

Name	Title
Mr. Prashant Kohli	CEO & Director
Mr. Amresh Kumar Ph.D.	VP of Program Management
Ms. Carrie D'Andrea	VP of Clinical Operations
Mr. Robert J. DelAversano CPA	VP of Finance and Principal Financial & Accounting Officer
Dr. R. Loch MacDonald M.D., Ph.D.	Member of Scientific Advisory Board & Chief Medical Officer

FAQs

What is Grace Therapeutics Inc share price today?

Grace Therapeutics Inc share price today is $3.08 as on September 16, 2025 at 1:27 am IST at the close of the market. Grace Therapeutics Inc share today touched a day high of $3.14 and a low of $3.05.

What is the 52 week high and 52 week low for Grace Therapeutics Inc share?

Grace Therapeutics Inc share touched a 52 week high of $4.97 on December 5, 2024 and a 52 week low of $1.75 on April 7, 2025. Grace Therapeutics Inc stock price today i.e. September 16, 2025 at 1:27 am IST is closed at $3.08,which is 37.97% down from its 52 week high and 76.00% up from its 52 week low.

What is Grace Therapeutics Inc's market capitalisation today?

Grace Therapeutics Inc market capitalisation is $0.00T as on September 16, 2025 at 1:27 am IST.

How to invest in Grace Therapeutics Inc Stock (GRCE) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Grace Therapeutics Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Grace Therapeutics Inc Shares that will get you 0.4870 shares as per Grace Therapeutics Inc share price of $3.08 per share as on September 16, 2025 at 1:27 am IST.

What is the minimum amount required to buy Grace Therapeutics Inc Stock (GRCE) from India?

Indian investors can start investing in Grace Therapeutics Inc (GRCE) shares with as little as ₹88.141 or $1 (as of September 16, 2025 at 10:42 am IST) using the INDmoney app.
For example: If you want to invest $10 or ₹881.41 in Grace Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on September 16, 2025 at 10:42 am IST). Based on Grace Therapeutics Inc share’s latest price of $3.08 as on September 16, 2025 at 1:27 am IST, you will get 3.2468 shares of Grace Therapeutics Inc. Learn more about fractional shares .